Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure

  • Cannie, Douglas E.|||0000-0001-6298-922X
  • Syrris, Petros|||0000-0002-2363-8758
  • Protonotarios, Alexandros|||0000-0001-8595-7212
  • Bakalakos, Athanasios
  • Pruny, Jean-François
  • Ditaranto, Raffaello
  • Martinez-Veira, Cristina
  • Larrañaga-Moreira, Jose M.
  • Medo, Kristen
  • Bermudez Jimenez, Francisco J.|||0000-0003-0325-7349
  • Ben Yaou, Rabah
  • Leturcq, France
  • Mezcua, Ainhoa Robles
  • Marini-Bettolo, Chiara|||0000-0003-3795-6017
  • Cabrera-Borrego, Eva|||0000-0003-2997-2391
  • Reuter, Chloe
  • Limeres Freire, Javier|||0000-0003-3644-9494
  • Rodríguez Palomares, José F.|||0000-0002-7229-9780
  • Mestroni, Luisa
  • Taylor, Matthew R G.
  • Parikh, Victoria N.
  • Ashley, Euan A.
  • Barriales-Villa, Roberto|||0000-0002-6721-3487
  • Jiménez-Jáimez, Juan|||0000-0001-5541-898X
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Charron, Philippe|||0000-0002-1782-1118
  • Biagini, Elena|||0000-0003-0295-0440
  • García Pinilla, José Manuel|||0000-0001-5999-5741
  • Bourke, John
  • Savvatis, Konstantinos|||0000-0003-1966-1880
  • Wahbi, Karim|||0000-0001-7682-7387
  • Elliott, Perry M.|||0000-0003-3383-3984
Emery-Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants also cause end-stage heart failure (ESHF) and malignant ventricular arrhythmia (MVA). This study aimed to better characterize the cardiac complications of EMD variants. Consecutively referred EMD variant-carriers were retrospectively recruited from 12 international cardiomyopathy units. MVA and ESHF incidences in male and female variant-carriers were determined. Male EMD variant-carriers with a cardiac phenotype at baseline (EMD ) were compared with consecutively recruited male LMNA variant-carriers with a cardiac phenotype at baseline (LMNA ). Longitudinal follow-up data were available for 38 male and 21 female EMD variant-carriers [mean (SD) ages 33.4 (13.3) and 43.3 (16.8) years, respectively]. Nine (23.7%) males developed MVA and five (13.2%) developed ESHF during a median (inter-quartile range) follow-up of 65.0 (24.3-109.5) months. No female EMD variant-carrier had MVA or ESHF, but nine (42.8%) developed a cardiac phenotype at a median (inter-quartile range) age of 58.6 (53.2-60.4) years. Incidence rates for MVA were similar for EMD and LMNA (4.8 and 6.6 per 100 person-years, respectively; log-rank P =.49). Incidence rates for ESHF were 2.4 and 5.9 per 100 person-years for EMD and LMNA , respectively (log-rank P =.09). Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Stochastic coupled map model of subcellular calcium cycling in cardiac cells

  • Romero Castañeda, Luis
  • Álvarez Lacalle, Enrique
  • Shiferaw, Yohannes
In this study, we analyze a nonlinear map model of intracellular calcium (Ca) and voltage in cardiac cells. In this model, Ca release from the sarcoplasmic reticulum (SR) occurs at spatially distributed dyadic junctions that are diffusively coupled. At these junctions, release occurs with a probability that depends on key variables such as the SR load and the diastolic interval. Using this model, we explore how nonlinearity and stochasticity determine the spatial distribution of Ca release events within a cardiac cell. In particular, we identify a novel synchronization transition, which occurs at rapid pacing rates, in which the global Ca transient transitions from a period 2 response to a period 1 response. In the global period 2 response dyadic junctions fire in unison, on average, on alternate beats, while in the period 1 regime, Ca release at individual dyads is highly irregular. A close examination of the spatial distribution of Ca reveals that in the period 1 regime, the system coarsens into spatially out-of-phase regions with a length scale much smaller than the system size, but larger than the spacing between dyads.We have also explored in detail the coupling to membrane voltage. We study first the case of positive coupling, where a large Ca transient promotes a long action potential duration (APD). Here, the coupling to voltage synchronizes Ca release so that the system exhibits a robust period 2 response that is independent of initial conditions. On the other hand, in the case of negative coupling, where a large Ca transient tends to shorten the APD, we find a multitude of metastable states which consist of complex spatially discordant alternans patterns. Using an analogy to equilibrium statistical mechanics, we show that the spatial patterns observed can be explained by a mapping to the Potts model, with an additional term that accounts for a global coupling of spin states. Using this analogy, we argue that Ca cycling in cardiac cells exhibits complex spatiotemporal patterns that emerge via first or second order phase transitions. These results show that voltage and Ca can interact in order to induce complex subcellular responses, which can potentially lead to heart rhythm disorders., Peer Reviewed, Postprint (published version)
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations

  • Ruiz-García, Raquel
  • Martínez Hernández, Eugenia
  • García-Ormaechea, Milagros
  • Español-Rego, Marta|||0000-0001-5497-2276
  • Sabater, Lidia
  • Querol, Luis|||0000-0002-4289-8264
  • Illa, Isabel|||0000-0002-2186-2684
  • Dalmau, Josep|||0000-0001-5856-2813
  • Graus Ribas, Francesc|||0000-0002-8924-8322
SOX1 autoantibodies are considered markers of small cell lung cancer (SCLC) and paraneoplastic neurological syndromes (PNS) and are usually determined by commercial line blot in many clinical services. Recent studies suggested that SOX1 autoantibodies also occur in patients with neuropathies unrelated to SCLC, questioning the value of SOX1 autoantibodies as paraneoplastic biomarkers. Here, we compared the specificity and sensitivity of a commercial line blot (Euroimmun, Lübeck, Germany) with those of an in house cell-based assay (CBA) with HEK293 cells transfected with SOX1. Overall, 210 patients were included in the study, 139 patients with polyneuropathies without SCLC, and 71 with disorders associated with SOX1 autoantibodies detected with the in-house CBA. Forty one of these 71 cases had been referred to our laboratory for onconeuronal antibody assessment and 30/71 were patients with known PNS and SCLC. None of the patients with polyneuropathies had SOX1 autoantibodies by either line blot or CBA (specificity of the immunoblot: 100%; 95%C.I.: 97.8-100). Among the 71 patients with CBA SOX1 autoantibodies, only 53 were positive by line blot (sensitivity: 74.6%; 95%C.I.: 62.9-84.2). Lung cancer was detected in 37/41 (90%; 34 with SCLC) patients referred for onconeuronal antibody assessment and 34 of them also had a PNS. Our study confirms the association of SOX1 autoantibodies with SCLC and PNS. The line blot test misses 25% of the cases; therefore, to minimize the frequency of false negative results we recommend the use of a confirmatory test, such as CBA, in patients suspected to have a SCLC-related PNS.